Surrozen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
May 11, 2022 at 04:16 pm EDT
Share
Surrozen, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 7.95 million compared to USD 13.02 million a year ago. Basic loss per share from continuing operations was USD 0.23 compared to USD 0.72 a year ago.
Surrozen, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a range of organs and tissues. The Company's lead product candidates are multi-specific, antibody-based therapeutics that mimic the roles of naturally occurring Wnt or R-spondin proteins, which are involved in activation and enhancement of the Wnt pathway. Its two technologies, Surrozen Wnt signal Activating Protein (SWAP) and Surrozen Wnt signal Enhancers Engineered for Tissue Specificity (SWEETS), enable it to potently and selectively modulate Wnt signaling through the generation of Wnt and R-spondin mimetics. SWAP molecules are designed to mimic the activity of naturally occurring Wnt proteins. SWEETS molecules are designed to amplify the body's response to naturally occurring Wnt proteins. Its product candidates include SZN-1326, SZN-043 and SZN-413.
SURROZEN, INC. 
